HOUSE_OVERSIGHT_015492.jpg

2.32 MB

Extraction Summary

5
People
8
Organizations
2
Locations
1
Events
3
Relationships
5
Quotes

Document Information

Type: Article / educational material (evidence file)
File Size: 2.32 MB
Summary

This document appears to be a page from an educational publication (Nautilus Education) discussing 'orphan diseases' (rare diseases). It contrasts the struggles of a modest family (the Topics) with the efforts of Michele Wrubel, an affluent Connecticut woman with calpainopathy whose husband, Lee Wrubel, is a venture capitalist in the medical field. The document includes a House Oversight stamp (HOUSE_OVERSIGHT_015492), indicating it was collected as evidence, potentially due to the connection of the Wrubels to the broader investigation.

People (5)

Name Role Context
Marijana Topic Parent/Subject
Runs a daycare center, mother of children with rare disease.
Niko Topic Parent/Subject
Works for a lumber company, father of children with rare disease.
Michele Wrubel Subject/Advocate
49-year-old stay-at-home parent from Connecticut with calpainopathy; described as affluent and well-connected crusade...
Lee Wrubel Spouse/Professional
Michele's husband; holds MD/MPH from Tufts and MBA from Columbia; venture capitalist in the medical field.
Isabel Jordan Chair
Chair of the Rare Disease Foundation.

Timeline (1 events)

2008
Gene sequencing came of age; Lee Wrubel tracked down a neurologist.
Unknown

Locations (2)

Relationships (3)

Michele Wrubel Spouse Lee Wrubel
Wrubel’s husband, Lee
Marijana Topic Spouse Niko Topic
her husband and the childrens’ father, Niko
Michele Wrubel Advocate/Hope The Topic Family
For the Topics, Wrubel may be their best hope.

Key Quotes (5)

"“I’m definitely a fighter, and will try and walk for as long as I can.”"
Source
HOUSE_OVERSIGHT_015492.jpg
Quote #1
"“Without hope, there’s no life.”"
Source
HOUSE_OVERSIGHT_015492.jpg
Quote #2
"“To make a difference in this disease, you need money and meetings,” she says. “Researchers are not going to study a disease unless there’s money behind it to fund the research.”"
Source
HOUSE_OVERSIGHT_015492.jpg
Quote #3
"“Families have to advocate”"
Source
HOUSE_OVERSIGHT_015492.jpg
Quote #4
"“If you don’t know what you’re looking for, they don’t know what to tell you or how to help you”"
Source
HOUSE_OVERSIGHT_015492.jpg
Quote #5

Full Extracted Text

Complete text extracted from the document (3,741 characters)

NAUTILUS EDUCATION | BETA PRODUCT
“I’m definitely a fighter, and will try and walk for as long as I can.”
researchers and funds devoted to them. With quiet stoicism, the Topics have accepted that modern medicine may not have a solution for their daughters’ disease. Still, says Marijana, “Without hope, there’s no life.”
Following a current grassroots trend in medicine, many individuals with orphan diseases do not wait for the medical industry to care about them. Facing long odds, they are forced to raise money to find a potential cure themselves. But the Topics live by modest means. Marijana runs a daycare center and her husband and the childrens’ father, Niko, works for a lumber company. They are in no position to mount a quest.
But then there’s Michele Wrubel, 49, a stay-at-home parent from Connecticut who has calpainopathy. For years, Wrubel has been a passionate crusader for a cure. Affluent and well connected, she doesn’t varnish the truth about what it has taken to make the medical industry pay attention to her. “To make a difference in this disease, you need money and meetings,” she says. “Researchers are not going to study a disease unless there’s money behind it to fund the research.” For the Topics, Wrubel may be their best hope.
THE GLOBAL GENES PROJECT, an advocacy group, estimates 350 million people suffer from orphan diseases worldwide. Most rare diseases are genetic and tend to appear early in life. About 30 percent of children who have them die before reaching their fifth birthday. The rest battle their conditions throughout life, as most orphan diseases have no cure. Out of the 7,000 orphan diseases identified to date, with about 250 new ones added annually, less than 400 can be treated therapeutically.
This year the European Commission gave 144 million euros to develop 200 new therapies and the National Institute of Health allocated $3.5 billion to research orphan diseases. Yet some diseases are so rare that they remain stepchildren even among orphans. As a result, they receive little research attention and funding. Neither do they fit the list of billable insurance procedures. There’s no standard healthcare path to diagnosis, let alone treatment. Similar to the Topics, many patients go through an ordeal, which Marijana describes as “a blur,” only to find out that medicine can’t help them.
Orphan disease organizations, such as the National Organization for Rare Disorders and the Rare Disease Foundation, encourage patients to take matters into their own hands. “Families have to advocate,” says Isabel Jordan, chair of the Rare Disease Foundation. She encourages patients to form organizations, find new methods of funding, and push for research.
“Push for research” could be Michele Wrubel’s calling card. She was diagnosed with muscular dystrophy in her mid-20s. But even though calpainopathy was identified nearly 20 years ago—about the same time Wrubel got her initial diagnosis—it took almost the entire second half of her life to determine that she was afflicted with calpainopathy. There were no clinical procedures that would lead to a diagnosis.
“It took a really long time and a very concerted effort,” says Wrubel, who walks with canes, submitting to a wheelchair for long trips or when in crowded places. “If you don’t know what you’re looking for, they don’t know what to tell you or how to help you,” she says.
In 2008, gene sequencing came of age, which aided physicians in diagnosing muscular dystrophy subtypes. That year, Wrubel’s husband, Lee, who holds a medical degree and a master’s in public health from Tufts, an MBA from Columbia University, and is a venture capitalist in the medical field, tracked down a neurologist
32
HOUSE_OVERSIGHT_015492

Discussion 0

Sign in to join the discussion

No comments yet

Be the first to share your thoughts on this epstein document